Zila Adds Four Major European Markets for Its Proprietary Oral Cancer Screening Product,...

Zila Adds Four Major European Markets for Its Proprietary Oral Cancer Screening Product, ViziLite Plus

Company Names Dentaid Marketing Partner for Spain, France, Germany
and Portugal
PHOENIX--(Business Wire)--
Zila, Inc. (NASDAQ:ZILA) today announced that it has selected
Dentaid to be the exclusive distributor of ViziLite(R) Plus with
TBlue(TM), Zila's proprietary oral cancer screening product, in Spain,
France, Germany and Portugal. Dentaid is the market leader among
dental distributors in France and Spain, and has recently established
a significant presence in the German market. Terms of the agreement
were not disclosed.

ViziLite(R) Plus with TBlue(TM) is now available to 55% of the
people in the Western and Eastern EU-member countries; Zila previously
announced that it had selected distributors for the product in the
United Kingdom, Ireland, Greece and Cyprus.

"The marketing of ViziLite Plus in Spain, France, Germany, and
Portugal provides a solid core of countries in Europe with an
important new oral cancer screening tool," said David Bethune,
chairman and chief executive officer of Zila. "We believe Dentaid's
direct selling force will communicate the unique attributes of
ViziLite Plus to the dental healthcare community and build it into a
leading brand in these markets."

ViziLite(R) Plus with TBlue(TM), Zila's flagship product for the
early detection of oral abnormalities that could lead to cancer, is
the first and only adjunctive medical device cleared by the FDA for
use in a population at increased risk for oral cancer.

"ViziLite Plus is a much needed oral cancer screening product for
the practitioners that we call on," said Enric Masdevall, president
and chief executive officer of Dentaid Europe. "Given that 25% of oral
cancers occur in people who do not smoke and have no other behavioral
risk factors, it is imperative that every adult, particularly those at
high risk for oral cancer, be screened at least once a year. ViziLite
Plus is a proven technology and will be a valuable aid in screening
for precancerous lesions and early stage cancers before they reach
more severe stages."

The combined population of Spain, France, Germany and Portugal
exceeds 195 million.

About Oral Cancer and ViziLite Plus

Oral cancer is the sixth leading cause of cancer worldwide, and in
the U.S., one person dies every hour from the disease. According to
American Cancer Society data, nearly as many women will be diagnosed
with oral cancer as with cervical cancer this year. The key to
reducing the impact of this disease is early detection, yet prior to
the introduction of ViziLite Plus the only screening tools available
were the manual and visual exam, which helps explain why the mortality
and morbidity associated with oral cancer have not markedly improved
in the past 40 years. Worldwide clinical trials have demonstrated that
the conventional visual/tactile examination may fail to identify up to
40% of cancers and precancers. In other studies the addition of
ViziLite Plus to conventional examination has been shown in the
literature to result in identification of 100% of pathological
lesions.

ViziLite Plus, an oral screening technology that utilizes a
chemiluminescent light source (ViziLite) and a patented vital tissue
dye (TBlue), helps dentists and dental technicians identify and
evaluate abnormalities in the mouth that could potentially harbor
pathologic changes. The ViziLite Plus exam takes only minutes and is
totally painless and non-invasive.

Oral Cancer Risk factors:

-- age - all adults

-- tobacco use - particularly if combined with heavy alcohol
consumption

-- heavy alcohol consumption

-- excessive sun exposure to the lips

-- sexually transmitted virus exposure (HPV)

A recent report in the New England Journal of Medicine suggests
that exposure to the sexually transmitted human papillomavirus number
16 (HPV16), causes oropharyngeal cancer (a type of oral cancer), and
may help explain the increasing incidence of the disease in younger
people.

About Dentaid

Dentaid is a recognized leader with international prestige in the
field of oral hygiene. Dentaid was created in 1980 with a clear
mission to investigate, develop and commercialize products aimed at
preventing, diagnosing and treating diseases produced by dental
bacterial plaque, by either physical, chemical or biological means.
The aim of Dentaid is to improve the oral health of the general
population by creating products that not only offer the best
solutions, but that are backed scientifically by dental professionals.

About Zila, Inc.

Zila, Inc., is a fully integrated oral diagnostic company
dedicated to the prevention, detection and treatment of oral cancer
and periodontal disease. ViziLite(R) Plus with TBlue(TM), the
company's flagship product for the early detection of oral
abnormalities that could lead to cancer, is the first and only
adjunctive medical device cleared by the FDA for use in a population
at increased risk for oral cancer. In addition, Zila designs,
manufactures and markets a suite of proprietary products sold
exclusively and directly to dental professionals for periodontal
disease, including the Rotadent(R) Professional Powered Brush, the
Pro-Select Platinum(R) ultrasonic scaler and a portfolio of oral
pharmaceutical products for both in-office and home-care use.

This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934. These forward-looking
statements are based largely on Zila's expectations or forecasts of
future events, can be affected by inaccurate assumptions and are
subject to various business risks and known and unknown uncertainties,
a number of which are beyond the Company's control. Therefore, actual
results could differ materially from the forward-looking statements
contained herein. A wide variety of factors could cause or contribute
to such differences and could adversely affect revenue, profitability,
cash flows and capital needs. There can be no assurance that the
forward-looking statements contained in this press release will, in
fact, transpire or prove to be accurate. For a more detailed
description of these and other cautionary factors that may affect
Zila's future results, please refer to Zila's Form 10-K for its fiscal
year ended July 31, 2007 and Form 10-Q for the quarter ended April 30,
2008.

For more information about the company and its products, please
visit www.zila.com.

PondelWilkinson Inc.
Robert Jaffe, 310-279-5969 (Investors)

Copyright Business Wire 2008